In preclinical studies , our group showed that the addition of HDACi , including VPA , to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase ( TP ) , the key enzyme converting capecitabine to 5-FU , and by downregulating thymidylate synthase ( TS ) , the 5-FU target .